Newsletter Signup | Join Community
Opdivo® superior to single agent Taxotere for treatment of recurrent NSCLC
BLU-667 targets RET fusion proteins and can be used to treat 1-2% of NSLC patients with the RET mutation.
Tecentriq® Improves NSCLC survival when combined with Avastin & chemotherapy Regardless of PD-L1 Status.
Alcensa, Xalkori, and several other precision cancer medicines target ALK positive lung cancer and improve treatment.
What is the evidence and current recommendations for lung cancer screening?
FDA Approval Suggests Keytruda® Combined With Chemotherapy May Become New Standard Initial Treatment for Patients
The addition of Keytruda to Alimta - Platinum Chemotherapy Improves Survival in Non Small Cell Lung Cancer
Cyramza With Taxotere Offers Modest Increase in Overall Survival in NSCLC
The US Food and Drug Administration approves Keytruda for treatment of advanced SCLC.
Study suggests that first line chemotherapy + Iressa is a new standard treatment option for EGFR + NSCLC
Tarceva™ Improves Survival in Non-Small Cell Lung Cancer
I have small cell lung cancer; radiation to prevent spread to the brain has been recommended but…
HER 2 + Lung Cancer Treatment? https://coloradocancerblogs…
Dana Farber and MDACC discover why anti-PD 1 immunotherapy doesnt work in some patients and work to…
High incidence of ROS 1 false negative tests reported by U Colorado researchers. http://www…